<DOC>
	<DOCNO>NCT02377661</DOCNO>
	<brief_summary>The aim prospective , randomised , open-label , multicentre clinical trial enhance blood pressure control primary care introduce standardise simplify titration regime single pill combination ( SPC ) , comprise angiotensin receptor blocker , calcium channel blocker hydrochlorothiazide .</brief_summary>
	<brief_title>Lowering Blood Pressure Primary Care Vienna</brief_title>
	<detailed_description>Rationale Hypertension single large contributor mortality worldwide , account 13 % death globally . Approximately 30 % adult population suffer hypertension diagnose treat , 30-50 % adequately control blood pressure . At present , importance hypertension fundamental risk factor inadequately address among many patient physician . Design The aim prospective , randomised , open-label , multicentre clinical trial enhance blood pressure control primary care introduce standardise simplify titration regime single pill combination ( SPC ) , comprise angiotensin receptor blocker , calcium channel blocker hydrochlorothiazide . The trial randomise 42 family doctor resident specialist internal medicine ( enrol 840 patient treat untreated hypertension ) either experimental care standard care hypertension , latter accord 2013 European Society Cardiology Guidelines Management Arterial Hypertension . Practitioners randomise experimental care up-titrate antihypertensive therapy SPCs 4-week interval target blood pressure &lt; 140/90 mmHg reach respective follow-up ( Figure 1 ) . Study Outcomes The primary efficacy endpoint proportion patient achieve target office blood pressure 6 month follow-up . The main secondary endpoint improvement 24h ambulatory blood pressure ( ABPM ) profile , measure inclusion 6 month follow-up . Safety assessment include evaluation treatment emergent adverse event , particularly hospitalisation , worsen renal function , peripheral oedema hypotension .</detailed_description>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>Written inform consent office blood pressure â‰¥ 140/90 mmHg ACE inhibitor intolerance ( experimental arm ) Malignant disease life expectancy &lt; 6 month Women childbearing potential ( ICH definition ) breastfeeding Contraindications allergies olmesartan , amlodipine hydrochlorothiazide ( experimental arm ) Chronic kidney disease grade IV V ( eGFR &lt; 30 ml/min ) Recent myocardial infarction stroke within precede 3 month Participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>